Results 81 to 90 of about 2,234,624 (258)
Oxaliplatin is a platinum-based chemotherapeutic used for cancer treatment. Its use associates with peripheral neuropathies and chronic gastrointestinal side-effects.
Rhian Stavely (5374472) +9 more
core +1 more source
GC cells enhance glutamine accumulation by upregulating SLC1A5 expression. This upregulation not only boosts GC cell proliferation, but also outcompetes CD8+ T cells for glutamine and suppresses their antitumor immunity. Mechanistically, METTL7A deficiency in GC induces SLC1A5 overexpression via an m6A‐dependent pathway and N‐glycosylation ...
Mingjun Sun +16 more
wiley +1 more source
Overcoming Drug Resistance by Paclitaxel Resistance in Triple‐Negative Breast Cancer
In the murine triple‐negative breast cancer (TNBC) model, chemotherapy effectively increases tumor neoantigen burden (TNB). Here, the study constructs a liposomal nanovaccine using antigens derived from in vitro chemotherapy‐treated paclitaxel‐resistant TNBC 4T1 cells.
Bo Chen +10 more
wiley +1 more source
Supramolecular mercaptosuccinic acid‐capped CdTe core‐type quantum dot‐encapsulated proteoliposome assemblies (MSA‐CdTe QD PLs) have been developed to study and unambiguously demonstrate real‐time transporter‐mediated turnover translocation of Pt(II)‐based complexes by transmembrane Cu(I) P‐type ATPase pumps (CopA).
Madujika A. Horadigala Gamage +7 more
wiley +2 more sources
Background Oxaliplatin-based chemotherapy is the first-line treatment for colorectal cancer (CRC). However, oxaliplatin resistance remains a major challenge contributing to treatment failure and poor prognosis. An increased capacity for DNA damage repair
Xingwu Liu +5 more
doaj +1 more source
Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro [PDF]
AbstractBackgroundDrug resistance remains a great challenge in the treatment of gastric cancer. The goal of this study was to explore the anti-tumor effects and mechanism of cytokine-induced killer (CIK) cell combined with oxaliplatin (L-OHP) in human oxaliplatin-resistant gastric cancer cells.MethodsAfter producing oxaliplatin-resistant gastric cancer
Zhao Qun +5 more
openaire +3 more sources
Chemotherapy leverages tumor‐cell autophagy to reshape the colorectal cancer immune microenvironment. Autophagy degrades FBXW2 to promote C/EBPβ‐mediated TIMP‐2 transcription and MMP‐9 suppression, driving intra‐tumoral CD8+ T‐cell infiltration. Targeting MMP‐2/9 or restoring TIMP‐2 overcomes chemo‐resistance in autophagy‐deficient tumors. ABSTRACT The
Bing Cheng +12 more
wiley +1 more source
This review highlights an emerging anticancer approach integrating platinum agents into photodynamic therapy (PDT) and photoactivated chemotherapy (PACT) systems, further augmented by cancer cell membrane‐ and organelle‐targeting. By directing photoactivated platinum complexes from nontargeted distribution to cancer cells or defined subcellular sites ...
Shu Chen +3 more
wiley +2 more sources
The Role of microRNAs in Regulating Cancer Cell Response to Oxaliplatin-Containing Regimens
Oxaliplatin (cyclohexane-1,2-diamine; oxalate; platinum [2+]) is a third-generation chemotherapeutic drug with anticancer effects. Oxaliplatin has a role in the treatment of several cancers.
Ali Tavakoli Pirzaman MD +9 more
doaj +1 more source
Spatial Au+ Mapping Reveals a Self‐Amplifying Anti‐Tumor Immunity Loop Driven by Au(I) Complexes
The first report of spatial Au+ mapping of a representative gold complex (Au9). Macrophages, DCs, and tumor cells ranked as the top three in Au+ enrichment after Au9 treatment. Interestingly, Au9 treatment could induce ferroptosis and suppress cellular cholesterol, further eliciting a self‐amplifying anti‐tumor immunity loop.
Zhongren Xu +5 more
wiley +1 more source

